Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Products under Development by Stage of Development | 7 | 1 |
| Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Products under Development by Therapy Area | 8 | 1 |
| Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Products under Development by Indication | 9 | 1 |
| Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Products under Development by Companies | 12 | 2 |
| Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Therapeutics Assessment | 14 | 6 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 2 |
| Assessment by Molecule Type | 18 | 2 |
| Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Companies Involved in Therapeutics Development | 20 | 3 |
| Genentech, Inc. | 20 | 1 |
| Protagonist Therapeutics Inc. | 21 | 1 |
| Takeda Pharmaceutical Company Limited | 22 | 1 |
| Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drug Profiles | 23 | 11 |
| etrolizumab Drug Profile | 23 | 2 |
| PTG-100 Drug Profile | 25 | 2 |
| Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease Drug Profile | 27 | 1 |
| Small Molecules to Antagonize Integrin Alpha4 and Integrin Beta7 for Inflammatory Bowel Disease Drug Profile | 28 | 1 |
| vedolizumab Drug Profile | 29 | 5 |
| Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Dormant Projects | 34 | 1 |
| Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Discontinued Products | 35 | 1 |
| Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Featured News &Press Releases | 36 | 15 |
| May 24, 2016: Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week Annual Meeting | 36 | 1 |
| May 17, 2016: Protagonist Therapeutics to Present New Data on PTG-100 at Digestive Disease Week 2016 | 37 | 1 |
| Mar 19, 2016: New Data Presented at European Crohn's and Colitis Organisation Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment | 37 | 1 |
| Jan 08, 2016: Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100 | 38 | 1 |
| Oct 19, 2015: Takeda Presents Vedolizumab Data at the 2015 American College of Gastroenterology Annual Meeting and United European Gastroenterology Week | 39 | 2 |
| Jul 10, 2015: NICE recommends treatment for severe Crohn s disease | 41 | 1 |
| May 19, 2015: New biologic treatment for ulcerative colitis ENTYVIO (vedolizumab) now available in Canada after key work by Canadian researchers | 41 | 1 |
| May 19, 2015: New biologic treatment for ulcerative colitis ENTYVIO now available in Canada after key work by Canadian researchers | 42 | 2 |
| Mar 13, 2015: Treatment for chronic painful bowel condition to get NHS funding approval | 44 | 1 |
| Nov 10, 2014: Encycle Therapeutics developing lead molecule to tackle inflammatory bowel disease | 44 | 1 |
| Nov 10, 2014: Partnership announcement to tackle inflammatory bowel disease | 45 | 1 |
| Oct 02, 2014: Takeda Presents New Interim Phase 3 Maintenance Data that Support the Long-Term Efficacy of Vedolizumab in Patients with Ulcerative Colitis and Crohn s Disease | 46 | 1 |
| Jun 16, 2014: ENTYVIO (vedolizumab) Now Available in the United States for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis and Crohn's Disease | 47 | 1 |
| May 28, 2014: Takeda Receives European Commission Marketing Authorisation for Entyvio (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease | 48 | 1 |
| May 20, 2014: FDA Approves Takeda's Entyvio for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease | 49 | 2 |
| Appendix | 51 | 2 |
| Methodology | 51 | 1 |
| Coverage | 51 | 1 |
| Secondary Research | 51 | 1 |
| Primary Research | 51 | 1 |
| Expert Panel Validation | 51 | 1 |
| Contact Us | 51 | 1 |
| Disclaimer | 52 | 1 |